Esketamine vs Sufentanil for Endoscopy Sedation: Clinical Trial
- * RSI Success: The success rate of rapid sequence intubation (RSI) was substantially higher in the Sufentanil (Suf) group (98.6%) compared to the Esketamine (Esk) group (88.9%), P*...
- In essence, the study suggests that Sufentanil may be associated with a higher RSI success rate and greater sedation, while Esketamine may require higher propofol doses and result...
Here’s a breakdown of the key findings from the provided text:
Key Results:
* RSI Success: The success rate of rapid sequence intubation (RSI) was substantially higher in the Sufentanil (Suf) group (98.6%) compared to the Esketamine (Esk) group (88.9%), P* = 0.022.
* Propofol Dosage: Patients in the Esketamine group received a significantly higher total dosage of propofol during the endoscopy (126.3 ± 58.0 mg) compared to the Sufentanil group (112.8 ± 50.4 mg), *P = 0.036.
* MOAA/S Score: The mean Modified Observer’s Assessment of Alertness/Sedation (MOAA/S) score was significantly lower (indicating less sedation) in the Esketamine group (2.7 ± 1.7) compared to the Sufentanil group (3.1 ± 1.6), P* = 0.029.
* Endoscopy Time: There was no statistically notable difference in the time to complete the endoscopy between the two groups (P* = 0.247).
* Recovery Time: There were no statistically significant differences in recovery time as measured by MOAA/S or Aldrete scores.
* Adverse Reactions: 12 patients experienced mild adverse reactions in the Post-Anesthesia Care Unit (PACU), which resolved with symptomatic treatment. Common reactions included SpO2 reduction, low HR, hypotension, cough, dizziness, abdominal pain, and distension.
In essence, the study suggests that Sufentanil may be associated with a higher RSI success rate and greater sedation, while Esketamine may require higher propofol doses and result in less sedation.